Phase III Study of Lampalizumab in patients with geographic atrophy secondary to AMD 31/03/2014
Description
Phase III, Multi-center, Randomized, Double-Masked, Sham-Controlled Study of Efficacy and Safety of Lampalizumab intravitreal injections Administered Monthly for 24 Months in Patients with Geographic Atrophy Secondary to AMD.
If you are interested in taking part in a clinical trial, please call us at 935 950 155 and we will assess whether you are eligible. Further information on trials at research projects.
Author
Доктор Jordi Monés, M.D., Ph.D.
Номер лицензии COMB: 22.838
Директор
Доктор Медицины и Хирургии
Специалист по Офтальмологии
Специалист по лечению Сетчатки, Макулы и Стекловидного тела
01/01/2015
FOVISTA: Clinical Trial for subfoveal neovascular age-related macular degeneration
19/03/2014
Clinical trial in antiretroviral-naive patients with choroidal neovascularization secondary to AMD
20/12/2014
MPL4 GA: A phase I study in subjects with geographic atrophy secondary to dry age-related macular degeneration
20/12/2014
Oral Omega 3 GA. A phase II in subjects with geographic atrophy secondary to AMD
